EFFICACY OF SILODOSIN (UROREC®) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: THE MAXIMUM DECREASE OF BLADDER OUTLET OBSTRUCTION INDEX.

Abstract

One of the main causes of lower urinary tract symptoms in men over the age of 40 years old is benign prostatic hyperplasia (BPH), which according to the research is detected in 26.2% of men of this age group. The purpose of this study was to evaluate the efficacy of the use of silodosin (Urorec®) at dosage 8 mg once a day for relief of obstructive symptoms of BPH in men over 40 years old. From September 2016 till December 2017 144 men (residents of Almaty, the Republic of Kazakhstan) aged from 56 to 81 years old (63.9 [95% CI: 63.2, 64.5]) were included into the study with a diagnosis of benign prostatic hyperplasia. Uroflowmetry (Qmax determination) was performed to all patients initially, after 7, 14, 30, 60 and 120 days from initiation of treatment. IPSS questionnaires were filled initially, after 30, 60 and 120 days from the start of treatment, and 21 men underwent a complex urodynamic study with determination of PdetQmax, Qmax and BOOI (at baseline and after 120 days). A significant decrease in bladder outlet obstruction index was observed with silodosin reception (Urorec®) 8 mg once daily (-28.8 [95% CI: -28.2, -29.5] or -44.5% [95% CI: -43.4%, - 45.5%] (p <0.001)), a decrease in IPSS scores after 30, 60 and 120 days from initiation of treatment (-6.3 [95% CI: -5.9, -6.7], -6.5 [95% CI: -6.1, - 6.9], -6.8 [95% CI: -6.4, -7.2] respectively (p <0.001)), an increase in Qmax after 7, 14, 30, 60 and 120 days from initiation of treatment (+1.1 mL/s [95% CI: 1.0 mL/s, 1.2 mL/s], +1.6 mL/s [95% CI: 1.5 mL/s, 1.7 mL/s], +2.4 mL/s [95% CI: 2.3 mL/s, 2.5 mL/s], +2.5 mL/s [95% CI: 2.4 mL/s, 2.6 mL/s], +2.5 mL/s [95% CI: 2.4 mL/s, 2.7 mL/s] respectively (p <0.001)). The data obtained in the study allow us to recommend silodosin (Urorec®) at a dosage of 8 mg once a day as a first-line drug for the pathogenetic treatment of bladder outlet obstruction due to benign prostatic hyperplasia.

• Authors: A Khamzin, R Frolov
• Journal: Georgian medical news (Georgian Med News) Issue 276 Pg. 18-23 (Mar 2018) ISSN: 1512-0112 [Print] Georgia (Republic)
• PMID: 29697376 (Publication Type: Journal Article)

Chemical References

• Adrenergic alpha-1 Receptor Antagonists
• Indoles
• silodosin

Topics

• Adrenergic alpha-1 Receptor Antagonists (therapeutic use)
• Aged
• Aged, 80 and over
• Humans
• Indoles (therapeutic use)
• Male
• Middle Aged
• Prostatic Hyperplasia (complications, drug therapy, physiopathology)
• Urinary Bladder Neck Obstruction (drug therapy, etiology, physiopathology)